V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10008313 | 10004778 | 1.76 | 78 | Curative (C) | 2016-12-18 | 2017-12-08 | Capecitabine | 02 | N | 10481844 | CAPECITABINE |
| 10008314 | 10004779 | 1.68 | 63.9 | Palliative (P) | 2015-07-25 | 2015-08-15 | Carboplatin + Vinorelbine IV | 02 | N | 10482068 | PEMETREXED |
| 10008315 | 10004780 | 1.9 | 84.6 | Palliative (P) | 2017-08-20 | 2017-08-20 | CHLORAMBUCIL + OBINUTUZUMAB | 2 | null | 10482137 | CODOX M |
| 10008316 | 10004781 | 1.69 | 96.8 | Palliative (P) | 2018-02-01 | 2018-08-17 | AML18 PILOT TRIAL | N | N | 10482223 | CABOZANTINIB |
| 10008317 | 10004782 | 1.73 | 80.3 | Palliative (P) | null | 2016-11-28 | POMALIDOMIDE | 2 | y | 10482327 | OFATUMUMAB |
| 10008318 | 10004784 | 1.53 | 54.2 | Curative (C) | 2018-12-04 | 2019-02-28 | Bortezomib +/- Dexamethasone | N | N | 10482534 | CARBOPLATIN + PACLITAXEL + RT |
| 10008319 | 10004787 | null | 78 | Adjuvant (A) | 2016-06-29 | 2016-06-29 | Bortezomib +/- Dexamethasone | 2 | N | 10482890 | CAPECITABINE + IRINOTECAN |
| 10008320 | 10007418 | 1.63 | 86.7 | Palliative (P) | null | 2014-11-11 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10482982 | CHLORAMBUCIL + RITUXIMAB |
| 10008321 | 10004794 | 1.85 | 101.5 | Palliative (P) | 2016-03-24 | 2016-04-14 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 10483645 | CISPLATIN + GEMCITABINE |
| 10008322 | 10004795 | 1.78 | 79.8 | null | 2014-03-07 | 2014-03-20 | Bortezomib + MELPHALAN | 02 | N | 10483677 | CETUXIMAB + RT |
| 10008323 | 10004798 | 1.7 | 85.7 | Adjuvant (A) | 2016-12-20 | 2016-12-20 | Enzalutamide | 2 | N | 10484074 | EOX |
| 10008324 | 10004799 | 1.73 | 88.15 | Curative (C) | 2017-06-12 | 2017-06-18 | CETUXIMAB + IRINOTECAN + MDG | N | null | 10484131 | AML18 TRIAL |
| 10008325 | 10004800 | 1.74 | 84.7 | Palliative (P) | 2016-06-14 | 2016-06-14 | OXALIPLATIN | 02 | N | 10484169 | CLARITY TRIAL |
| 10008326 | 10004800 | null | null | Palliative (P) | 2018-06-01 | 2018-06-02 | Docetaxel + Nintedanib | N | N | 10484169 | PAZOPANIB |
| 10008327 | 10004802 | 1.62 | null | Palliative (P) | 2016-03-18 | 2016-04-08 | Cabazitaxel | N | N | 10484317 | RADIUM 223 |
| 10008328 | 10007426 | 1.71 | 77.3 | Palliative (P) | 2016-04-24 | 2016-04-25 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 10484424 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10008329 | 10004805 | 1.7 | null | Palliative (P) | 2016-11-30 | 2017-02-05 | BEAM + Alemtuzumab Allo SCT | 02 | N | 10484515 | MELPHALAN |
| 10008330 | 10004809 | 1.78 | 55.5 | Palliative (P) | 2018-02-12 | 2018-02-12 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 02 | N | 10484711 | OBINUTUZUMAB |
| 10008331 | 10004810 | 1.55 | 55 | Adjuvant (A) | 2017-08-09 | 2017-08-09 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | 10484808 | DOCETAXEL + TRASTUZUMAB |
| 10008332 | 10007429 | 1.67 | 76.7 | Disease modification (D) | 2017-03-26 | 2017-06-22 | Capecitabine (14 day) + Irinotecan | null | null | 10484984 | DACARBAZINE |
| 10008333 | 10004814 | 1.81 | 93 | Palliative (P) | 2016-09-02 | 2016-09-02 | CAPECITABINE + IRINOTECAN | 02 | N | 10485023 | CAPECITABINE + GEMCITABINE |
| 10008334 | 10004819 | 1.75 | 88.6 | Adjuvant (A) | 2015-11-30 | 2015-12-30 | Capecitabine (21days) + Carboplatin | N | N | 10485352 | CETUXIMAB + OXALIPLATIN + MDG |
| 10008335 | 10004821 | null | 66 | Palliative (P) | 2018-04-24 | 2018-09-21 | Cetuximab 14 day | N | N | 10485667 | VINORELBINE |
| 10008336 | 10004825 | 1.8 | 86.7 | Palliative (P) | 2017-01-22 | 2017-02-07 | Brentuximab | 02 | N | 10486032 | MELPHALAN |
| 10008337 | 10004828 | 1.75 | 78.2 | Curative (C) | 2016-05-05 | 2016-05-27 | MYELOMA XI TRIAL | N | N | 10486052 | CAPECITABINE + IRINOTECAN |
| 10008338 | 10004829 | null | 98 | Palliative (P) | 2017-11-29 | 2018-03-19 | Capecitabine (21days) + Carboplatin | N | null | 10486090 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10008339 | 10004832 | 1.8 | 70.5 | Palliative (P) | 2018-03-04 | 2018-03-14 | FLUOROURACIL + MITOMYCIN + RT | N | N | 10486417 | ENZALUTAMIDE |
| 10008340 | 10004836 | 1.76 | 88.3 | Palliative (P) | 2016-05-18 | 2016-05-23 | Cisplatin + Pemetrexed | 02 | N | 10486606 | ECF |
| 10008341 | 10004839 | null | 93.6 | Palliative (P) | 2019-02-09 | 2019-02-09 | CYCLOPHOSPHAMIDE + RITUXIMAB + Dexamethasone | 02 | N | 10486800 | GEMCITABINE + NAB-PACLITAXEL |
| 10008342 | 10004841 | 1.7 | 71.6 | Palliative (P) | 2016-08-24 | 2018-02-05 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 10486870 | VINORELBINE |
| 10008343 | 10004844 | 1.64 | 85.5 | Palliative (P) | null | 2017-11-18 | Cytarabine HD + Rituximab | 2 | null | 10487248 | BENDAMUSTINE + OBINUTUZUMAB |
| 10008344 | 10004846 | 1.7 | 50.9 | Palliative (P) | 2015-09-03 | 2016-03-30 | Chlorambucil | 02 | N | 10487275 | CAV |
| 10008345 | 10004849 | 1.78 | 56.3 | Palliative (P) | 2016-11-10 | 2016-12-30 | ECX | 02 | null | 10487421 | RADIUM 223 |
| 10008346 | 10004852 | 1.77 | null | Neo-adjuvant (N) | 2018-08-04 | 2018-08-04 | Erlotinib | 2 | N | 10487753 | CETUXIMAB + IRINOTECAN + MDG |
| 10008347 | 10004855 | 1.7 | 76.1 | Adjuvant (A) | 2016-08-02 | 2016-08-05 | CARBOPLATIN + RT | N | null | 10487949 | FLUOROURACIL + MITOMYCIN + RT |
| 10008348 | 10004857 | 1.71 | 66.5 | Curative (C) | 2018-03-25 | 2018-06-17 | Capecitabine + Cisplatin + RT | N | N | 10487958 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10008349 | 10008996 | 1.73 | 101.85 | Curative (C) | 2016-06-06 | 2016-06-19 | Enzalutamide | 2 | N | 10488007 | CLADRIBINE |
| 10008350 | 10004861 | 1.63 | 0 | Curative (C) | 2018-05-08 | 2018-07-23 | Hydroxycarbamide | 02 | N | 10488337 | FEC + DOCETAXEL |
| 10008351 | 10004863 | 1.73 | 134 | Palliative (P) | 2017-05-17 | 2017-05-27 | CAPECITABINE + RT | 02 | N | 10488696 | RIALTO TRIAL |
| 10008352 | 10004866 | 1.66 | 81 | Disease modification (D) | 2016-03-04 | 2016-03-30 | Capecitabine + Cisplatin + RT | 02 | N | 10488841 | METHOTREXATE |
| 10008353 | 10007452 | 1.68 | null | Curative (C) | 2017-12-24 | 2018-01-14 | Cytarabine intrathecal | N | N | 10489029 | CISPLATIN + VINORELBINE + RT |
| 10008354 | 10004871 | 1.84 | 61.8 | Curative (C) | 2018-02-03 | 2018-09-08 | CARBOPLATIN + PACLITAXEL + RT | N | null | 10489110 | CRIZOTINIB |
| 10008355 | 10004873 | 1.63 | 70.5 | Adjuvant (A) | 2017-05-04 | 2017-05-07 | Bortezomib + Panobinostat | 02 | N | 10489184 | FLUOROURACIL + MITOMYCIN + RT |
| 10008356 | 10004875 | 1.7 | null | Adjuvant (A) | 2016-01-29 | 2016-01-29 | Cyclophosphamide oral | N | N | 10489253 | ERLOTINIB |
| 10008357 | 10004876 | 0 | 57 | Palliative (P) | 2017-03-08 | 2017-03-29 | CLADRIBINE | 02 | N | 10489385 | ECX |
| 10008358 | 10004879 | 1.71 | 46 | Disease modification (D) | 2018-04-02 | 2018-08-08 | Bortezomib + MELPHALAN | N | N | 10489503 | PERTUZUMAB |
| 10008359 | 10004881 | 1.79 | 83.2 | Neo-adjuvant (N) | 2017-06-15 | 2017-06-15 | REMODLB TRIAL | 02 | N | 10489526 | RIALTO TRIAL |
| 10008360 | 10004881 | 1.7 | 101.7 | Palliative (P) | 2017-10-12 | 2017-10-20 | DARATUMUMAB | N | N | 10489526 | CISPLATIN + PEMETREXED |
| 10008361 | 10007460 | 1.73 | 68.4 | Palliative (P) | 2018-11-18 | 2018-11-20 | CRIZOTINIB | N | N | 10489705 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10008362 | 10007460 | 1.81 | 84 | Neo-adjuvant (N) | 2017-10-10 | 2017-10-18 | Irinotecan | 02 | N | 10489705 | R CODOX M |